Bovie Medical Corp. (NYSE:BVX) is pulling a pair of electrosurgical devices off the market to settle a patent infringement lawsuit with Salient Surgical Technologies and Medtronic Inc. (NYSE:MDT).
Bovie Medical said the agreement calls for it to yank its Seer and Boss monopolar and bipolar saline-enhanced radio-frequency devices from the worldwide market, in return for $750,000 from Medtronic and the chance to strike an OEM contract with Salient Surgical. (Bovie already has such a deal going with Medtronic.)
The lawsuit, filed last summer in the U.S. District Court for Delaware, accused Bovie of violating a trio of patents licensed to Portsmouth, N.H.-based Salient. That company’s Aquamantys system competes with the Bovie products and is based on patents licensed from Medtronic.
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Salient, founded as TissueLink Medical in 1999, banked $15 million from its seventh funding round in January 2010. Its backers include Medtronic — which owns a nearly 9 percent stake in the company — TLM Investors, QuestMark Advisors and the RiverVest Venture Fund.
Bovie Medical president and CEO Andrew Makrides said the company decided to settle after considering the cost of continuing to fight the suit and the possibility that it still might lose the case.
“After carefully weighing the considerable costs of continued litigation and the inherent uncertainty in this type of action, management concluded that this settlement was in the best interest of the company and its shareholders,” makrides said. “With this issue behind us, we can focus increased resources and efforts on our J-Plasma technology and other new products.”
Related articles
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
- Medtronic cancels contract with another purchasing organization (medcitynews.com)
- Medtronic acquires rights to technology that can help in sinus surgery (medcitynews.com)
- Medtronic’s canceled supply contracts yield savings, rising shares (medcitynews.com)
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.